Your browser doesn't support javascript.
loading
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830].
Jhaveri, K L; Wang, X V; Makker, V; Luoh, S-W; Mitchell, E P; Zwiebel, J A; Sharon, E; Gray, R J; Li, S; McShane, L M; Rubinstein, L V; Patton, D; Williams, P M; Hamilton, S R; Conley, B A; Arteaga, C L; Harris, L N; O'Dwyer, P J; Chen, A P; Flaherty, K T.
Afiliación
  • Jhaveri KL; Department of Medicine, Memorial Sloan-Kettering Center, New York, USA. Electronic address: jhaverik@mskcc.org.
  • Wang XV; Biostatistics, E-A Biostatistical Center, Boston, USA.
  • Makker V; Gynecologic Medical Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
  • Luoh SW; Knight Cancer Institute, Oregon Health Science University, Portland, USA.
  • Mitchell EP; Medical Oncology, Thomas Jefferson University, Philadelphia, USA.
  • Zwiebel JA; Investigational Drug Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
  • Sharon E; Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, USA.
  • Gray RJ; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA.
  • Li S; Department of Biostatistics, Dana Farber Cancer Institutes, Boston, USA.
  • McShane LM; Biometric Research Branch, National Cancer Institute, Bethesda, USA.
  • Rubinstein LV; Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institute of Health, Bethesda, USA.
  • Patton D; Center for Biomedical, Informatics & Information Technology, National Cancer Institute, Bethesda, USA.
  • Williams PM; Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, USA.
  • Hamilton SR; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, USA.
  • Conley BA; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
  • Arteaga CL; Department of Internal Medicine, University of Texas Southwestern, Dallas, USA.
  • Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, USA.
  • O'Dwyer PJ; University of Pennsylvania, Philadelphia, USA.
  • Chen AP; CTEP, National Cancer Institute, Bethesda, USA.
  • Flaherty KT; Cancer Center, Massachusetts General Hospital, Boston, USA.
Ann Oncol ; 32(8): 1068, 2021 Aug.
Article en En | MEDLINE | ID: mdl-34099371
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article